



Vivimed

Date : November 14, 2011

To

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

Dear Sir/Madam,

Subject : Outcome of Board Meeting

Ref. : Clause 41 of Listing Agreement

With reference to captioned subject and pursuant to Clause 41 of Listing Agreement entered into with the Stock Exchange, we are hereby forwarding unaudited Stand Alone and Consolidated Financial Results for the quarter and half year ended on September 30, 2011 approved by the Board of Directors at their meeting held on November 14, 2011.

1) Highlights of Stand Alone Results are :

- YoY Sales up by 73% to Rs 1990 mn.
- YoY Net Profit up by 43% to Rs 201.90 mn.

Highlights of Consolidated Results are :

- YoY Sales up by 30% to Rs 2492 mn.
- YoY Net Profit up by 6 % to Rs. 248.10 mn.

2) On the organic growth the Board was appraised of the progress on:

- Acquisition of land for the Company's Sector Specific Pharma SEZ at Srikakulam District, Andhra Pradesh, which has been completed. The company is well in line with completion of the other formalities required to obtain the final sanction to enable commencement of the construction works for creation of further manufacturing facilities.

Total Investment outlay (including land):	Rs 1200 mn
Land & Development works:	Rs 450 mn
Phase I facilities: (March 2013)	Rs 250 mn



**Vivimed**

Phase II facilities: (March 2014)

Rs 500 mn

- Formulation dosage facility project at Choutuppal, near Hyderabad. The civil works have already started and the company expects completion of the facility by June 2013 and to start commercial production by December 2013.

Total Investment outlay:	Rs 400 mn
Land & Civil works: Amount spent:	Rs 25 mn
Facility completion: (June 2013)	Rs 375 mn

- Expansion of existing manufacturing facilities at Bonthapally, Andhra Pradesh has already commenced and will be completed by June 2012. Investment outlay : Rs 100 Mn.
- Expansion of existing manufacturing facilities at Bidar, Karnataka to be completed by June 2012. Investment outlay: Rs 100 mn.
- Expansion of Pharma capacity at Jeedimetla, Hyderabad involving an investment outlay of Rs 100 mn will be completed by Feb 2012.

3) Inorganic growth – acquisitions completed and targeted:

The company has acquired a Kolkata based pharmaceutical company named Klar Sehen Pvt Ltd having a strong presence in North Eastern states, Bihar and Andhra Pradesh. The company operates in a niche ophthalmic segment and owns about 50 trademarks and well known brands.

The Company also invested into a similar Hyderabad based pharmaceutical company named Octantis Nobel Labs Pvt Ltd, distributing various formulations with a presence in Andhra Pradesh and certain Eastern states.

Further the company is also on the verge of closing in on an acquisition, which will enhance its market presence in Specialty chemicals and Pharmaceuticals for which the Financial closure has been achieved and the acquisition transaction nearing closure.

- 4) The company, realizing the increasing complexities with varying Accounting standards, tax practices and disclosure requirements with respect to its facilities and office in various locations across the globe, has decided to appoint Internal and Statutory Auditors of repute. This would ensure that these issues are addressed to bring about more tax efficiencies, de-risk and mitigate the currency translation risks and also create greater synergy in planning and implementation relating to these issues.

Board thus considered proposals for appointment of internationally acclaimed audit firms such as KPMG, Deloitte, Grant & Thornton and took note that at the next AGM, one of these should be appointed as Statutory Auditors of the company. The statutory auditors so appointed will also handle the taxation related matters of the Company.

Further the Board was also informed that either Price Water House Coopers (PWC) or Ernst & Young will be appointed as Internal Auditors of the Company effective the 1st day of January 2012. Necessary steps are being taken to discuss this subject with them for giving effect to this requirement.





Vivimed


The company is also required to give effect to these changes pursuant to the agreements with Private Equity Investors.

- 5) The Company also detailed the steps needed to reduce the current Working Capital Cycle from the existing SIX months to a level of FOUR months in a timeframe of three succeeding quarters by adopting the following measures:
 - a) Improved Logistics and Distribution network that will enable the company to reduce the transit time in effecting deliveries to customers and advance the invoicing time;
 - b) Increase interaction and coordination with top and key customers to align the production schedules with their planned intake and reduce the pressure on need for higher inventory retention levels. The company now has dedicated key account managers for each of the top rung customers and the objective in creating this structure is essentially the need for bringing in efficiencies in planning of supply and demand schedules;
 - c) Enhance the customer base to Tier II and Tier III levels that permeate the second rung customers as well as the locations and negotiate softer credit terms to improve on the receivables days.
- 6) Board took note of recently completed fund raising exercise from certain private Equity Investors as well as Term financing Institutions. The Board was informed that the funds raised will be sufficient for implementing its organic growth plans.

This is for your information and record.

Thanking You,

For VIVIMED LABS LIMITED


SANTOSH VARALWAR

MANAGING DIRECTOR & CEO



Encl : As Above

VIVIMED LABS LIMITED
STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED SEPTEMBER 30th, 2011

Particulars	(INR in mn)				
	3 Months ended		6 Months ended		12 Months
	Unaudited	Unaudited	Unaudited	Audited	
	30-09-2011	30-09-2010	30-09-2011	30-09-2010	31-03-2011
1. (a) Net Sales/Income from Operations	951.08	608.90	1,990.38	1,151.51	3,098.10
(b) Other Operating Income	1.45	0.15	1.65	0.24	2.87
Total Income(1+2)	952.54	609.05	1,992.03	1,151.75	3,100.97
2. Expenditure	765.49	482.64	1,611.28	914.62	2,594.97
a. (Increase) / decrease in stock in trade and work in progress	(56.31)	12.75	(62.91)	(15.70)	(44.50)
b. Consumption of Raw Materials	648.96	352.84	1,259.65	690.85	1,988.45
c. Purchase of Traded Goods	-	-	-	-	-
d. Employee Cost	24.61	18.33	53.43	34.49	105.39
e. Depreciation	24.79	9.14	38.91	17.77	50.31
f. Other Expenditure	123.43	89.58	322.20	187.21	495.33
g. Total	765.49	482.64	1,611.28	914.62	2,594.97
3. Profit from Operations before Other Income, Interest and Exceptional items (1-2)	187.05	126.41	380.75	237.13	506.00
4. Other Income	-	-	-	-	-
5. Profit before Interest and Exceptional items (3+4)	187.05	126.41	380.75	237.13	506.00
6. Interest	69.68	35.94	128.34	71.27	176.31
7. Profit after Interest but before Exceptional items (5-6)	117.36	90.48	252.41	165.86	329.69
8. Exceptional items	-	-	-	-	-
9. Profit(+)/ Loss(-) from ordinary activities before Tax (7+8)	117.36	90.48	252.41	165.86	329.69
10. Tax Expenses	23.48	13.87	50.50	26.16	52.05
11. Net profit(+)/Loss(-) from ordinary activities after Tax(9-10)	93.88	76.61	201.91	139.70	277.64
12. Extraordinary Items (net of tax expense Rs....)	-	-	-	-	-
13. Net Profit(+)/Loss(-) for period(11-12)	93.88	76.61	201.91	139.70	277.64
14. Paid-up Equity Share Capital (Face value of Rs 10/- each)	124.44	99.65	124.44	99.65	101.64
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year					
16. Earnings Per Share(EPS)					

(INR in mm)



a. Basic EPS before extraordinary items for the period, for the year to date and for the previous year	7.54	7.69	16.23	14.02	27.32
b. Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year	7.46	7.69	14.49	14.02	23.82
17. Public Shareholding	74,08,900	47,64,231	74,08,900	47,64,231	50,46,200
- Number of shares	59.54%	47.81%	59.54%	47.81%	49.65%
- Percentage of shareholding					
18. Promoters and Promoter Group Shareholding **					
a) Pledged / Encumbered					
- Number of shares	10,52,455	10,52,455	10,52,455	10,52,455	10,52,455
- Percentage of shares (as a % of the total share capital of the company)	20.90%	20.24%	20.90%	20.24%	20.56%
- Promoter group)	8.46%	10.56%	8.46%	10.56%	10.36%
b) Non - encumbered					
- Number of shares	39,82,587	41,48,218	39,82,587	41,48,218	40,65,361
- Percentage of shares (as a % of the total share capital of the company)	79.10%	79.76%	79.10%	79.76%	79.44%
- Promoter group)	32.00%	41.63%	32.00%	41.63%	40.00%

1. The above Standalone Results for the Quarter ended September 30th, 2011 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on November 14, 2011.
2. During the quarter ended September 30th, 2011 company has received one investor's complaint. No complaint was pending at the beginning of the quarter or lying unsolved at the end of the quarter.
3. During the quarter under review the Company has made the following allotments: (a) 4,49,789 Equity Shares were allotted on July 11, 2011; (b) 18,30,137 Equity Shares allotted on September 29, 2011 & © 6,70,000 Compulsorily Convertible and Cumulative Preference Shares (CCPS) on September 29, 2011
4. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com
5. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
6. Impact of Foreign Exchange Fluctuations Amounting to Rs. 8 Million is not taken in accounts.
7. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)

MANAGING DIRECTOR & CEO

Place: Hyderabad

Date: 14 / 11 / 2011



VIVIMED LABS LIMITED - STANDALONE
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE

(INR in mmt)

Particulars	3 Months ended		6 Months ended		ended
	Unaudited	Unaudited	Unaudited	Audited	
	30-09-2011	30-09-2010	30-09-2011	30-09-2010	31-03-2011
1. Segment Revenue (net sales/ income from each segment should be disclosed under this head)					
a.Speciality Chemicals Business	687.40	491.20	1,451.81	918.74	2,421.30
b.Pharma Business	263.68	117.71	538.56	232.78	676.80
Total	951.08	608.90	1,990.38	1,151.51	3,098.10
Less, Inter Segment Revenue	-	-	-	-	-
Net sales / Income from Operations	951.08	608.90	1,990.38	1,151.51	3,098.10
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment					
a.Speciality Chemicals Business	122.87	97.28	260.30	180.03	387.99
b.Pharma Business	64.18	29.13	120.45	57.10	118.01
Total	187.05	126.41	380.75	237.13	506.00
Less: 1. Interest	69.68	35.94	128.34	71.27	176.31
2. Other Un-allocable Expenditure	-	-	-	-	-
3. Un-allocable Income	-	-	-	-	-
Total Profit Before Tax	117.36	90.48	252.41	165.86	329.69
3. Capital Employed (Segment Assets - Segment Liabilities)					
a.Speciality Chemicals Business	5,593.18	3,434.32	5,593.18	3,434.32	3,495.71
b.Pharma Business	523.23	581.82	523.23	581.82	413.47
Total	6,116.41	4,016.14	6,116.41	4,016.14	3,909.18

For Vivimed Labs Limited

Place : Hyderabad
Date : 14 / 11 / 2011

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED (Standalone)

Statement of Assets and Liabilities as at September 30th, 2011

(INR in mm)

Particulars	3 Months ended as at 30-09-2011	3 Months ended as at 30-09-2010	6 Months ended as at 30-09-2011	6 Months ended as at 30-09-2010	Year Ended March 31st, 2011
Shareholders' Funds					
a) Capital	794.44	99.65	794.44	99.65	101.64
b) Warrant Application Money	99.75	79.60	99.75	79.60	88.64
c) Reserves & Surplus	2,254.57	1,224.82	2,254.57	1,224.82	1,348.83
Loan Funds	2,902.56	1,798.63	2,902.56	1,798.63	2,280.01
Deferred Tax Liability	156.89	172.82	156.89	172.82	156.90
TOTAL	6,208.22	3,375.51	6,208.22	3,375.51	3,976.02
Fixed Assets	2,074.36	1,448.09	2,074.36	1,448.09	1,611.62
Investments	386.56	34.88	386.56	34.88	33.99
Current Assets, Loans & Advances					
a) Inventories	771.58	612.41	771.58	612.41	667.05
b) Sundry Debtors	1,054.85	875.55	1,054.85	875.55	959.61
c) Cash & Bank Balances	939.47	54.92	939.47	54.92	86.32
d) Other Current Assets		-			
e) Loans & Advances	1,239.65	565.65	1,239.65	565.65	859.60
Less : Current Liabilities & Provisions					
a) Liabilities	229.47	210.79	229.47	210.79	174.93
b) Provisions	120.65	68.95	120.65	68.95	134.09
Miscellaneous Expenditure (Not Written off or Adjusted)	91.85	63.74	91.85	63.74	66.85
Profit and Loss Account	-	-	-	-	-
TOTAL	6,208.22	3,375.51	6,208.22	3,375.51	3,976.02



VIVIMED LABS LIMITED
CONSOLIDATED UN-AUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED SEPTEMBER 30th, 2011

(INR in mm)

Particulars	3 Months ended		6 Months ended		12 Months
	Unaudited		Unaudited		Audited
	30-09-2011	30-09-2010	30-09-2011	30-09-2010	31-03-2011
1. (a) Net Sales/Income from Operations	1,287.02	1,056.83	2,492.43	1,906.67	4,160.01
(b) Other Operating Income	1.15	0.31	1.98	0.40	9.33
Total Income(1+2)	1,288.17	1,057.14	2,494.41	1,907.07	4,169.34
2. Expenditure	1,046.96	863.50	2,032.57	1,556.90	3,410.76
a. (Increase) / decrease in stock in trade and work in progress	(65.75)	13.74	(131.98)	(1.40)	(45.91)
b. Consumption of Raw Materials	807.05	648.11	1,508.96	1,141.54	2,415.58
c. Purchase of Traded Goods	-	-	-	-	-
d. Employee Cost	71.26	52.65	119.90	98.72	199.67
e. Depreciation	37.86	20.86	64.32	40.35	91.45
f. Other Expenditure	196.55	128.14	471.37	277.69	749.97
g. Total	1,046.96	863.50	2,032.57	1,556.90	3,410.76
3. Profit from Operations before Other Income, Interest and Exceptional items (1-2)	241.20	193.64	461.83	350.16	758.58
4. Other Income	-	(0.10)	-	-	-
5. Profit before Interest and Exceptional items (3+4)	241.20	193.54	461.83	350.16	758.58
6. Interest	79.11	37.85	144.18	75.40	205.96
7. Profit after Interest but before Exceptional items (5-6)	162.09	155.69	317.66	274.76	552.62
8. Exceptional items	-	-	-	-	-
9. Profit(+)/ Loss(-) from ordinary activities before Tax (7+8)	162.09	155.69	317.66	274.76	552.62
10. Tax Expenses	37.88	20.39	69.52	41.32	64.31
11. Net profit(+)/Loss(-) from ordinary activities after Tax(9-10)	124.21	135.30	248.13	233.44	488.32
12. Extraordinary Items (net of tax expense Rs.)	-	-	-	-	-
13. Net Profit(+)/Loss(-) for period(11-12)	124.21	135.30	248.13	233.44	488.32
14. Paid-up Equity Share Capital (Face value of Rs 10/- each)	124.44	99.65	124.44	99.65	101.64
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year					-
16. Earning Per Share(EPS)					



a. Basic EPS before extraordinary items for the period, for the year to date and for the previous year	9.98	13.58	19.94	23.43	48.04
b. Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year	9.86	13.58	17.81	23.43	41.90
17. Public Shareholding					
- Number of shares	74,08,900	47,64,231	74,08,900	47,64,231	50,46,200
- Percentage of shareholding	59.54%	47.81%	59.54%	47.81%	49.65%
18. Promoters and Promoter Group Shareholding **					
a) Pledged / Encumbered					
- Number of shares	10,52,455	10,52,455	10,52,455	10,52,455	10,52,455
promoter group)	20.90%	20.24%	20.90%	20.24%	20.56%
- Percentage of shares (as a % of the total share capital of the company)	8.46%	10.56%	8.46%	10.56%	10.36%
b) Non - encumbered					
- Number of shares	39,82,587	41,48,218	39,82,587	41,48,218	40,65,361
and Promoter group)	79.10%	79.76%	79.10%	79.76%	79.44%
- Percentage of shares (as a % of the total share capital of the company)	32.00%	41.63%	32.00%	41.63%	40.00%

1. The above Standalone Results for the Quarter ended September 30th, 2011 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on November 14, 2011.
2. During the quarter ended September 30th, 2011 company has received one investor's complaint. No complaint was pending at the beginning of the quarter or lying unsolved at the end of the quarter.
3. During the quarter under review the Company has made the following allotments : (a) 4,49,789 Equity Shares on July 11, 2011; (b) 18,30,137 Equity Shares on September 29, 2011 & © 6,70,000 Compulsorily Convertible and Cumulative Preference Shares (CCPS) on September 22, 2011.
4. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com
5. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
6. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH KARALWAR)

MANAGING DIRECTOR & CEO

Place : Hyderabad

Date : 14/11/2011



VIVIMED LABS LIMITED - CONSOLIDATED

SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE

(INR in mm)

Particulars	3 Months ended		6 Months ended		Year Ended
	Unaudited	Audited	Unaudited	Audited	
	30-09-2011	30-09-2010	30-09-2011	30-09-2010	31-03-2011
1. Segment Revenue (Net Sales/Income from each segment should be disclosed under this head)					
a. Specialty Chemicals Business	1,086.14	838.71	2,111.32	1,571.48	3,729.00
b. Pharma Business	400.99	218.12	778.84	396.34	997.24
Total	1,487.13	1,056.83	2,890.16	1,967.82	4,726.24
Less : Inter Segment Revenue	200.11	-	397.73	61.15	566.23
Net sales / Income from Operations	1,287.02	1,056.83	2,492.43	1,906.67	4,160.01
2. Segment Results(Profit(+)/Loss(-) before tax and interest from each segment					
a.Speciality Chemicals Business	162.28	147.07	312.70	268.15	593.20
b. Pharma Business	78.91	46.47	149.13	82.02	165.37
Total	241.20	193.54	461.83	350.16	758.58
Less: 1.Interest	79.11	37.85	144.18	75.40	205.96
2. Other Un-allocable Expenditure net	-	-	-	-	-
3. Un-allocable Income	-	-	-	-	-
Total Profit Before Tax	162.08	155.69	317.65	274.76	552.61
3. Capital Employed (Segment Assets - Segment Liabilities)					
a.Speciality Chemicals Business	7,179.40	3,434.32	7,179.40	3,434.32	4,783.87
b. Pharma Business	940.21	581.82	940.21	581.82	595.19
Total	8,119.61	4,016.14	8,119.61	4,016.14	5,379.06

For Vivimed Labs Limited

Place : Hyderabad
Date : 14 / 11 / 2011

(SANTOSH VARALWAR)

MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED (Consolidated)

Statement of Assets and Liabilities as at September 30th, 2011

(INR in mm)

Particulars	3 Months ended as at 30-09-2011	3 Months ended as at 30-09-2010	6 Months ended as at 30-09-2011	6 Months ended as at 30-09-2010	Year Ended March 31st, 2011
Shareholders' Funds					
a) Capital	794.44	99.65	794.44	99.65	101.64
b) Warrant Application Money	99.75	79.60	99.75	79.60	88.64
c) Reserves & Surplus	2,728.80	1,529.53	2,728.80	1,529.53	1,776.82
Loan Funds	3,607.49	2,729.40	3,607.49	2,729.40	3,077.18
Deferred Tax Liability	147.15	161.89	147.15	161.89	146.52
TOTAL	7,377.63	4,600.06	7,377.63	4,600.06	5,190.80
Fixed Assets	2,311.37	1,791.07	2,311.37	1,791.07	1,814.58
Copyrights, Trade Marks, Intellectual Property, Goodwill	1,068.23	939.77	1,068.23	939.77	845.55
Investments	47.13	-	47.13	-	-
Current Assets, Loans & Advances	1,243.35	778.33	1,243.35	778.33	844.75
a) Inventories	1,286.82	1,188.07	1,286.82	1,188.07	1,275.55
b) Sundry Debtors	1,006.07	80.34	1,006.07	80.34	110.96
c) Cash & Bank Balances	-	-	-	-	-
d) Other Current Assets	785.19	288.59	785.19	288.59	915.56
e) Loans & Advances	229.01	370.95	229.01	370.95	467.10
Less : Current Liabilities & Provisions	233.44	159.01	233.44	159.01	216.02
a) Liabilities	91.91	63.88	91.91	63.88	66.97
b) Provisions	-	-	-	-	-
Miscellaneous Expenditure (Not Written off or Adjusted)	-	-	-	-	-
Profit and Loss Account	-	-	-	-	-
TOTAL	7,377.63	4,600.06	7,377.63	4,600.06	5,190.80

